Therefore, the impact of the GAL-9/TIM-3 axis depends on TME features and the specific immune cells involved, and additional studies are needed to unveil the complete molecular mechanism of the TIM-3/GAL-9 pathway in order to broaden its therapeutic applications for cancer therapy. Here, HAVCR2 is linked to cancer.